FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1513-1515 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sanders, G. D. Related Article by Neumann, P. J. PubMed Citation

The remarkable reduction of 50 percent or more in the age-adjusted mortality rate from coronary heart disease over the past four decades in the United States¹ has been driven by three parallel phenomena: an understanding of the risk factors that influence the likelihood and presentation of coronary events, the use of randomized trials to create an indisputable evidence base on which to make decisions, and the flexibility to change systems of care to incorporate new knowledge into practice. Despite the failure of some physicians to adopt proven interventions² and substantial disparities in the U.S. health care system,³ the reduction in . . . [Full Text of this Article]

Source Information

From the Department of Medicine, University of California, San Francisco, San Francisco.

Related Letters:

Medicare and Cost-Effectiveness Analysis
Schulman K. A., Smolkin M. T., Berger M., Honig P., Spatz I., Neumann P. J., Rosen A. B., Weinstein M. C., Goldman L.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:207-209, Jan 12, 2006. Correspondence

This article has been cited by other articles:

• Pandharipande, P. V., Gervais, D. A., Mueller, P. R., Hur, C., Gazelle, G. S. (2008). Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis. Radiology 248: 169-178 [Abstract] [Full Text]  
• Hillner, B. E., Smith, T. J. (2007). Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?. JCO 25: 611-613 [Full Text]  
• Losina, E., Walensky, R. P., Geller, A., Beddingfield, F. C. III, Wolf, L. L., Gilchrest, B. A., Freedberg, K. A. (2007). Visual Screening for Malignant Melanoma: A Cost-effectiveness Analysis. Arch Dermatol 143: 21-28 [Abstract] [Full Text]  
• Goldberger, Z., Lampert, R. (2006). Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies. JAMA 295: 809-818 [Abstract] [Full Text]  
• Anderson, K. P., Stevenson, L. W., Stevenson, W. G., Fauchier, L., Babuty, D., Sanders, G. D., Hlatky, M. A., Owens, D. K. (2006). Cost-Effectiveness of ICDs. NEJM 354: 205-207 [Full Text]  
• Schulman, K. A., Smolkin, M. T., Berger, M., Honig, P., Spatz, I., Neumann, P. J., Rosen, A. B., Weinstein, M. C., Goldman, L. (2006). Medicare and Cost-Effectiveness Analysis. NEJM 354: 207-209 [Full Text]